Income StatementBalance SheetCash FlowSegments
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Regeneron Pharmaceuticals holds $40.9B in total assets. Shareholders' equity is $31.4B against $2.7B in total debt. Cash and equivalents total $3.0B. The current ratio is 3.56 and debt-to-equity is 0.086. Based on the Q1 2026 filing.

Total Assets$40.9BTotal Stockholders Equity$31.4BLong Term Debt$2.0BCash And Equivalents$3.0BTotal Current Assets$18.2BTotal Current Liabilities$5.1B
Latest FilingQ1 2026
Report Date2026-04-29
Market Cap$67.0B
P/E Ratio15.14
ROE14.55%

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts payable$789.5M$705.5M$723.9M$903.8M$939.0M$1.0B
Accrued Progress Collections and Price Adjustments$185.7M$211.8M$206.3M$219.2M$208.7M$225.1M
Deferred revenue$627.7M$619.3M$481.9M$545.6M$553.0M$636.2M
Finance Lease Liability, Current————$0.0$720.0M
Operating lease liabilities, current$30.3M———$37.8M—
Total current liabilities$3.9B$3.6B$3.7B$4.4B$4.4B$5.1B

Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts receivable, net$6.2B$5.6B$5.6B$5.7B$5.7B$5.7B
Cash and cash equivalents$2.5B$3.1B$2.0B$2.5B$3.1B$3.0B
Finished goods$139.8M$110.0M$144.4M$169.7M$190.2M$160.5M
Short- term Investments$6.5B$5.3B$5.5B$5.9B$5.5B$5.8B
Raw materials$879.5M$838.5M$752.3M$710.0M$641.5M$630.7M
Work in process$1.3B$1.5B$1.5B$1.6B$1.6B$1.5B
Inventories$3.1B$3.2B$3.2B$3.3B$3.2B$3.1B
Other Inventory, Net$725.7M$773.9M$764.4M$808.8M$727.5M$787.9M
Prepaid expenses and other current assets$349.2M$468.9M$574.3M$595.6M$474.8M$620.9M
Restricted cash—$2.8M$19.8M$6.7M—$8.0M
Short-term investments$6.5B$5.3B$5.5B$5.9B$5.5B$5.8B
Total current assets$18.7B$17.6B$16.9B$18.0B$18.0B$18.2B
Trading Securities in Marketable Securities$159.8M$316.8M$316.8M$316.8M$334.0M$571.6M

Equity

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Additional paid-in capital$12.9B$13.2B$13.5B$13.8B$14.0B$14.4B
Accumulated other comprehensive income (loss)-$7.9M$29.1M$52.5M$69.0M$77.5M$11.9M
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding$0.0$0.0$0.0$0.0$0.0$0.0
Retained earnings$31.7B$32.4B$33.7B$35.0B$35.8B$36.4B
Share Repurchase Program - Amount Remaining—$3.9B$2.8B$2.2B—$688.2M
Total liabilities and stockholders' equity$37.8B$37.5B$38.2B$40.2B$40.6B$40.9B
Total stockholders' equity$29.4B$29.4B$29.9B$31.0B$31.3B$31.4B
Treasury stock$15.2B$16.2B$17.3B$17.9B$18.6B$19.4B

Non-Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Contract Liabilities, Non-Current$185.7M$211.8M$206.3M$219.2M$208.7M$225.1M
Finance lease liabilities$720.0M$720.0M$720.0M$720.0M$720.0M$0.0
Finance Lease Liabilities (Total)$720.0M———$720.0M—
Long-term debt$2.0B$2.0B$2.0B$2.0B$2.0B$2.0B
Accrued expenses and other liabilities$2.5B$2.2B$2.5B$3.0B$2.9B$2.7B
Deferred revenue, net of current portion$185.7M$211.8M$206.3M$219.2M$208.7M$225.1M
Operating Lease Liabilities (Total)$234.4M———$266.8M—
Other non-current liabilities$1.6B$1.7B$1.7B$1.9B$2.0B$2.1B
Total liabilities$8.4B$8.2B$8.3B$9.2B$9.3B$9.4B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Cumulative Cost Basis$14.3B$13.3B$14.0B$15.4B$15.6B$15.5B
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax$39.0M$17.7M$10.2M$6.0M$2.5M$28.3M
Gross Unrealized Gains$30.1M$57.0M$77.7M$93.2M$98.5M$40.9M
Total$14.3B$13.3B$14.0B$15.4B$15.6B$15.5B
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five$7.8B$8.0B$8.6B$9.5B$10.2B$9.6B
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One$6.5B$5.3B$5.5B$5.9B$5.5B$5.8B
Available for sale investments$14.3B$13.3B$14.0B$15.5B$15.7B$15.5B
Maturities after five years$0.0—$400.0K$66.0M$1.5M$98.4M
Trading securities, cost$159.8M$316.8M$316.8M$316.8M$334.0M$571.6M
Current maturities of long-term debt————$0.0$720.0M
Preferred Stock, Par or Stated Value Per Share$0.01$0.01$0.01$0.01$0.01$0.01
Preferred Stock, Shares Authorized30M30M30M30M30M30M
Preferred Stock, Shares Issued000000
Preferred Stock, Shares Outstanding000000
Share Repurchase Program, Remaining Authorized, Amount—$3.9B$2.8B$2.2B—$688.2M
Treasury stock, shares (in shares)28.2M29.7M31.6M32.7M33.7M34.7M

Non-Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Deferred Tax Assets and Other Non-Current Assets$1.1B$1.4B$1.5B$1.7B$1.8B$2.1B
Equity Securities (FV-NI) - Non-Current————$34.3M$48.7M
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments$159.8M$316.8M$316.8M$316.8M$334.0M$571.6M
Equity Securities (Non-Current)————$34.3M$48.7M
Investments - Amortized Cost Basis$159.8M$316.8M$316.8M$316.8M$334.0M$571.6M
Deferred tax assets$3.3B$3.4B$3.6B$3.8B$4.1B$4.2B
Other intangible assets—net$1.1B$1.2B$1.4B$1.4B$1.3B$1.3B
Long- term Investments$8.9B$9.3B$10.1B$10.3B$10.3B$9.8B
Other non-current assets$1.1B$1.4B$1.5B$1.7B$1.8B$2.1B
Property, plant and equipment, net$4.6B$4.7B$4.8B$5.0B$5.1B$5.3B
Software and Technology Licenses, Net$1.1B$1.4B$1.5B$1.7B$1.8B$2.1B
Total assets$37.8B$37.5B$38.2B$40.2B$40.6B$40.9B